Annual Congress Vienna 2009

Saturday, 12.09.2009
Sunday, 13.09.2009
Monday, 14.09.2009
Tuesday, 15.09.2009
Wednesday, 16.09.2009

Citations should be made in the following way: Authors. Title. Eur Respir J 2009; 34: Suppl. 53, abstract number.

Material from 2009:

4047 Abstracts
652 Slide presentations
300 Webcasts
93 Handouts
2150 e-posters
300 Multimedia files

Material from 2009: Show

Clinical management of pulmonary arterial hypertension

Oral Presentation
Chairs: G. Simonneau (Clamart, France), A. Peacock (Clydebank, United Kingdom)

Download all media

Oral sildenafil treatment in children with pulmonary arterial hypertension (PAH): results of a double-blind, placebo-controlled, dose-ranging study R. Barst, H. Richardson, I. Konourina, 1131 Study Group (New York, United States Of America; Sandwich, United Kingdom)
Effect of riociguat on haemodynamic parameters and exercise capacity in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH) H. A. Ghofrani, M. Hoeper, M. Halank, G. Staehler, G. Weimann, F. Grimminger, Study Investigators (Giessen, Hannover, Dresden, Loewenstein, Wuppertal, Germany)
The prognostic value of percent predicted six-minute walk distance in pulmonary arterial hypertension W. T. N. Lee, A. Peacock, M. Johnson (Glasgow, United Kingdom)
Tricuspid annular plane systolic excursion in scleroderma-related pulmonary arterial hypertension S. Mathai, C. Sibley, P. Forfia, H. Champion, A. Zaiman, R. Girgis, P. Hassoun (Baltimore, Philadelphia, United States Of America)
Right ventricular mechanical efficiency measured in PAH patients using PET Y. Y. Wong, G. Ruiter, M. Lubberink, P. Knaapen, P. Raijmakers, T. Marcus, N. Westerhof, W. van der Laarse, A. Vonk-Noordegraaf (Amsterdam, Netherlands)
*Clinical outcomes of pulmonary arterial hypertension in carriers of ACVRL1* (ALK1) mutation** D. Montani, B. Girerd, F. Coulet, B. Sztrymf, A. Yaici, X. Jaïs, A. Reis, V. Drouin-Garraud, A. Fraisse, O. Sitbon, G. Simonneau, F. Soubrier, M. Humbert (Clamart, France)
Prevalence and mechanism of pulmonary hypertension in sickle cell disease: a prospective multicentre french study F. Parent, D. Bachir, F. Lionnet, J. Inamo, L. Savale, F. Driss, G. Loko, S. Bennani, B. Maître, R. Girot, F. Galacteros, G. Simonneau (Clamart, Créteil, Paris, Le Kremlin Bicêtre, France; Fort de France, Le Lamentin, Martinique)
Treatment of pulmonary hypertension (PH) and sickle cell disease (SCD) with sildenafil (SILD) therapy (walk-phasst): interim report R. Barst, M. Gladwin, R. Machado, K. Hassell, N. Yovetich, V. Gordeuk, S. Gibbs, J. Little, G. Kato, C. Morris, R. Girgis, D. Badesch, L. Krishnamurti, D. Schraufnagel, E. Berman-Rosenzweig (New York, Pittsburgh, Chicago, Denver, Chapel Hill, Washington, Bronx, Bethesda, Oakland, Baltimore, United States Of America; London, United Kingdom)